Riverview Trust Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Riverview Trust Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55	Closed	-$24.6K	–	203
2026 Q1	$24.6K	Hold	55	–	–	0.03%	139
2025 Q4	$24.9K	Hold	55	–	–	0.03%	151
2025 Q3	$21.5K	Hold	55	–	–	0.03%	160
2025 Q2	$24.5K	Sell	55 -194	-78%	-$89.4K	0.03%	162
2025 Q1	$121K	Sell	249 -6	-2%	-$2.8K	0.12%	137
2024 Q4	$103K	Buy	255 +1	+0.4%	+$464	0.09%	154
2024 Q3	$118K	Buy	254 +60	+31%	+$28.8K	0.1%	151
2024 Q2	$90.9K	Hold	194	–	–	0.09%	165
2024 Q1	$81.1K	Buy	+194	New	+$82K	0.06%	185
2023 Q4	–	Sell	-194	Closed	-$67.5K	–	622
2023 Q3	$67.5K	Hold	194	–	–	0.06%	198
2023 Q2	$68.3K	Hold	194	–	–	0.06%	169
2023 Q1	$61.1K	Hold	194	–	–	0.06%	182
2022 Q4	$56K	Hold	194	–	–	0.05%	200
2022 Q3	$56K	Hold	194	–	–	0.05%	188
2022 Q2	$55K	Hold	194	–	–	0.05%	201
2022 Q1	$51K	Buy	+194	New	+$46K	0.04%	222

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Riverview Trust Company's VRTX Position: Q2 2026 in Review

Riverview Trust Company sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 55 shares — an estimated $24.6K sold.

Riverview Trust Company first reported a position in VRTX in Q1 2022 and held it in 16 quarters. The position peaked at $121K in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Riverview Trust Company reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Riverview Trust Company sold 55 Vertex Pharmaceuticals shares in Q2 2026, an estimated $24.6K.
Riverview Trust Company first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 16 quarters.
Riverview Trust Company's Vertex Pharmaceuticals position peaked at $121K in Q1 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Riverview Trust Company's 13F filing for Q2 2026, filed 3 Aug 2026.